We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Notice for mirdametinib (Merck Healthcare Pty Ltd)
Active ingredients
mirdametinib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
dispersible tablets; hard capsules
Indication
Treatment of neurofibromatosis type 1
Therapeutic area
Neurology